| Bioactivity | (1S,2S)-Bortezomib is an enantiomer of Bortezomib. Bortezomib is a cell-permeable, reversible, and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki of 0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is an anti-cancer agent and the first therapeutic proteasome inhibitor to be used in humans[1][2][3]. | ||||||||||||
| Name | (1S,2S)-Bortezomib | ||||||||||||
| CAS | 1132709-14-8 | ||||||||||||
| Formula | C19H25BN4O4 | ||||||||||||
| Molar Mass | 384.24 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
(1S,2S)-Bortezomib
CAS: 1132709-14-8 F: C19H25BN4O4 W: 384.24
(1S,2S)-Bortezomib is an enantiomer of Bortezomib. Bortezomib is a cell-permeable, reversible, and selective proteasome
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.